



## Snapshot of incidence, mortality and survival estimates by cancer type\*

| Dath saves sambined     | Incidence |         |               | Mortality |        |                    | Survival   |
|-------------------------|-----------|---------|---------------|-----------|--------|--------------------|------------|
| Both sexes combined     | Rank      | Cases   | Trend         | Rank      | Deaths | Trend              | 5-year (%) |
| All cancers             | _         | 229,200 | $\downarrow$  | _         | 84,600 | $\rightarrow$      | 64         |
| Lung and bronchus       | 1         | 29,600  | $\downarrow$  | 1         | 21,000 | <b>\rightarrow</b> | 22         |
| Breast                  | 2         | 28,000  | $\downarrow$  | 4         | 5,500  | $\downarrow$       | 89         |
| Colorectal              | 3         | 24,800  | $\downarrow$  | 2         | 9,600  | $\rightarrow$      | 67         |
| Prostate                | 4         | 24,000  | $\downarrow$  | 5         | 4,500  | <b>\rightarrow</b> | 91         |
| Bladder                 | 5         | 12,500  | $\rightarrow$ | 8         | 2,600  | $\rightarrow$      | 77         |
| Non-Hodgkin lymphoma    | 6         | 11,100  | $\rightarrow$ | 7         | 2,900  | $\downarrow$       | 69         |
| Melanoma                | 7         | 8,700   | <b>↑</b>      | 18        | 1,250  | $\rightarrow$      | 89         |
| Uterus (body, NOS)      | 8         | 8,000   | $\rightarrow$ | 17        | 1,400  | <b></b>            | 82         |
| Kidney and renal pelvis | 9         | 7,800   | $\rightarrow$ | 12,13,14  | 1,950  | $\rightarrow$      | 73         |
| Head and neck           | 10        | 7,400   | <b>1</b>      | 11        | 2,100  | $\rightarrow$      | 64         |
| Pancreas                | 11,12,13  | 6,700   | $\rightarrow$ | 3         | 5,600  | $\rightarrow$      | 10         |
| Leukemia                | 11,12,13  | 6,700   | $\downarrow$  | 6         | 3,100  | $\rightarrow$      | 61         |
| Thyroid                 | 11,12,13  | 6,700   | $\downarrow$  | 20        | 240    | $\rightarrow$      | 97         |
| Stomach                 | 14        | 4,000   | $\downarrow$  | 12,13,14  | 1,950  | $\rightarrow$      | 29         |
| Multiple myeloma        | 15        | 3,800   | $\uparrow$    | 15,16     | 1,600  | $\rightarrow$      | 50         |
| Liver                   | 16        | 3,300   | $\rightarrow$ | 15,16     | 1,600  | $\rightarrow$      | 22         |
| Brain/CNS               | 17        | 3,100   | $\downarrow$  | 9         | 2,400  | $\rightarrow$      | 22         |
| Ovary                   | 18        | 3,000   | $\downarrow$  | 12,13,14  | 1,950  | $\rightarrow$      | 44         |
| Esophagus               | 19        | 2,400   | $\downarrow$  | 10        | 2,300  | $\rightarrow$      | 16         |
| Cervix                  | 20        | 1,450   | $\downarrow$  | 19        | 380    | $\rightarrow$      | 74         |
| Testis                  | 21        | 1,200   | $\uparrow$    | 22        | 35     | $\rightarrow$      | 97         |
| Hodgkin lymphoma        | 22        | 1,050   | $\downarrow$  | 21        | 110    | $\rightarrow$      | 85         |
| All other cancers       | NA        | 23,800  | $\uparrow$    |           | 10,500 | $\rightarrow$      | NA         |

CNS=central nervous system; NOS=not otherwise specified; NA=not applicable

\*Source: <u>Canadian Cancer Statistics 2021</u> (Tables 1.2, 2.2 and 3.1). Both are available through <u>cancer.ca/statistics</u> and are accompanied by details on the data sources and methods used to obtain the estimates. Please reference accordingly. Email any questions to <u>stats@cancer.ca</u>.

| Cases    | Projected number of cancer diagnoses in Canada in 2021 (based on data to 2017)                                     |
|----------|--|
| Deaths   | Projected number of cancer deaths in Canada in 2021 (based on data to 2018)  |
| Rank     | Relative ranking of the 22 cancers from highest (1) to lowest (22) projected cases or deaths in 2021               |
| Survival | Predicted 5-year net survival for cases diagnosed in 2015—2017   |
| Trend    | Direction of most recent trend in incidence or mortality rate using data from 1984 to 2019; reflects statistically |
|          | significant increase $(\uparrow)$ or decrease $(\downarrow)$ or no change $(\rightarrow)$                          |



| Malas                   |       | Incidence |               |       | Mortality |               | Survival   |
|-------------------------|-------|-----------|---------------|-------|-----------|---------------|------------|
| Males                   | Rank  | Cases     | Trend         | Rank  | Deaths    | Trend         | 5-year (%) |
| All cancers             | _     | 118,200   | $\downarrow$  | _     | 44,600    | $\downarrow$  | 62         |
| Prostate                | 1     | 24,000    | $\downarrow$  | 3     | 4,500     | $\downarrow$  | 91         |
| Lung and bronchus       | 2     | 14,800    | $\downarrow$  | 1     | 10,800    | $\downarrow$  | 19         |
| Colorectal              | 3     | 13,700    | $\downarrow$  | 2     | 5,300     | $\downarrow$  | 66         |
| Bladder                 | 4     | 9,500     | $\rightarrow$ | 5     | 1,900     | $\downarrow$  | 77         |
| Non-Hodgkin lymphoma    | 5     | 6,200     | <b>↑</b>      | 8     | 1,650     | $\downarrow$  | 68         |
| Head and neck           | 6     | 5,400     | <b>↑</b>      | 9     | 1,500     | $\rightarrow$ | 64         |
| Kidney and renal pelvis | 7     | 5,200     | $\rightarrow$ | 12,13 | 1,250     | $\downarrow$  | 73         |
| Melanoma                | 8     | 4,700     | <b>↑</b>      | 15    | 790       | $\downarrow$  | 86         |
| Leukemia                | 9     | 4,000     | $\downarrow$  | 6     | 1,800     | $\downarrow$  | 60         |
| Pancreas                | 10    | 3,700     | <b>↑</b>      | 4     | 2,900     | $\rightarrow$ | 10         |
| Stomach                 | 11,12 | 2,600     | $\downarrow$  | 12,13 | 1,250     | $\downarrow$  | 27         |
| Liver                   | 11,12 | 2,600     | $\rightarrow$ | 11    | 1,300     | <b>↑</b>      | 22         |
| Multiple myeloma        | 13    | 2,300     | <b>↑</b>      | 14    | 930       | $\rightarrow$ | 50         |
| Esophagus               | 14    | 1,900     | $\downarrow$  | 7     | 1,750     | $\downarrow$  | 16         |
| Thyroid                 | 15,16 | 1,800     | $\rightarrow$ | 16    | 110       | <b>↑</b>      | 95         |
| Brain/CNS               | 15,16 | 1,800     | $\downarrow$  | 10    | 1,400     | $\rightarrow$ | 21         |
| Testis                  | 17    | 1,200     | <b>↑</b>      | 19    | 35        | $\downarrow$  | 97         |
| Hodgkin lymphoma        | 18    | 600       | $\downarrow$  | 17    | 65        | $\downarrow$  | 84         |
| Breast                  | 19    | 260       | <b>↑</b>      | 18    | 55        | $\rightarrow$ | 76         |
| Other cancers           | NA    | 12,200    | <b>^</b>      | NA    | 5,400     | $\downarrow$  | NA         |

CNS=central nervous system; NA=not applicable

\*Source: Canadian Cancer Statistics 2021 (Tables 1.2, 2.2 and 3.1). Both are available through cancer.ca/statistics and are accompanied by details on the data sources and methods used to obtain the estimates. Please reference accordingly. Email any questions to <a href="mailto:stats@cancer.ca">stats@cancer.ca</a>.

| Cases    | Projected number of cancer diagnoses in Canada in 2021 (based on data to 2017)   |
|----------|--|
| Deaths   | Projected number of cancer deaths in Canada in 2021 (based on data to 2018)  |
| Rank     | Relative ranking of the 22 cancers from highest (1) to lowest (22) projected cases or deaths in 2021   |
| Survival | Predicted 5-year net survival for cases diagnosed in 2015—2017   |
| Trend    | Direction of most recent trend in incidence or mortality rate using data from 1984 to 2019; reflects statistically significant increase $(\uparrow)$ or decrease $(\downarrow)$ or no change $(\rightarrow)$ |

Cancer-specific stats 2021





## Snapshot of incidence, mortality and survival estimates by cancer type, females\*

| Females                 | Incidence |         |               |      | Mortality | Survival      |            |
|-------------------------|-----------|---------|---------------|------|-----------|---------------|------------|
| remaies                 | Rank      | Cases   | Trend         | Rank | Deaths    | Trend         | 5-year (%) |
| All cancers             | _         | 110,900 | $\downarrow$  | _    | 40,000    | $\downarrow$  | 66         |
| Breast                  | 1         | 27,700  | $\downarrow$  | 2    | 5,400     | $\downarrow$  | 89         |
| Lung and bronchus       | 2         | 14,800  | $\downarrow$  | 1    | 10,300    | $\downarrow$  | 26         |
| Colorectal              | 3         | 11,100  | $\downarrow$  | 3    | 4,300     | $\downarrow$  | 67         |
| Uterus (body, NOS)      | 4         | 8,000   | $\rightarrow$ | 6    | 1,400     | <b>↑</b>      | 82         |
| Non-Hodgkin lymphoma    | 5         | 5,000   | <b>^</b>      | 8    | 1,250     | $\downarrow$  | 71         |
| Thyroid                 | 6         | 4,900   | $\downarrow$  | 19   | 130       | $\rightarrow$ | 98         |
| Melanoma                | 7         | 4,000   | <b>↑</b>      | 16   | 450       | $\downarrow$  | 92         |
| Bladder                 | 8,9,10    | 3,000   | $\rightarrow$ | 11   | 720       | $\downarrow$  | 75         |
| Pancreas                | 8,9,10    | 3,000   | $\rightarrow$ | 4    | 2,700     | $\downarrow$  | 9          |
| Ovary                   | 8,9,10    | 3,000   | $\downarrow$  | 5    | 1,950     | $\downarrow$  | 44         |
| Leukemia                | 11        | 2,700   | $\downarrow$  | 7    | 1,300     | $\downarrow$  | 61         |
| Kidney and renal pelvis | 12        | 2,600   | <b>^</b>      | 13   | 660       | $\downarrow$  | 73         |
| Head and neck           | 13        | 2,000   | $\rightarrow$ | 14   | 560       | $\downarrow$  | 65         |
| Multiple myeloma        | 14        | 1,500   | <b>^</b>      | 12   | 690       | $\downarrow$  | 51         |
| Cervix                  | 15        | 1,450   | $\downarrow$  | 17   | 380       | $\downarrow$  | 74         |
| Stomach                 | 16        | 1,400   | $\downarrow$  | 10   | 740       | $\downarrow$  | 32         |
| Brain/CNS               | 17        | 1,350   | $\downarrow$  | 9    | 1,050     | $\downarrow$  | 23         |
| Liver                   | 18        | 800     | $\rightarrow$ | 18   | 330       | <b>↑</b>      | 22         |
| Esophagus               | 19        | 560     | $\downarrow$  | 15   | 530       | $\downarrow$  | 17         |
| Hodgkin lymphoma        | 20        | 460     | $\rightarrow$ | 20   | 40        | $\downarrow$  | 86         |
| Other cancers           | NA        | 11,600  | <b>↑</b>      | NA   | 5,100     | $\downarrow$  | NA         |

CNS=central nervous system; NOS=not otherwise specified; NA=not applicable

\*Source: Canadian Cancer Statistics 2021 (Tables 1.2, 2.2 and 3.1). Both are available through cancer.ca/statistics and are accompanied by details on the data sources and methods used to obtain the estimates. Please reference accordingly. Email any questions to <a href="mailto:stats@cancer.ca">stats@cancer.ca</a>.

| Cases    | Projected number of cancer diagnoses in Canada in 2021 (based on data to 2017)                                     |
|----------|--|
| Deaths   | Projected number of cancer deaths in Canada in 2021 (based on data to 2018)  |
| Rank     | Relative ranking of the 22 cancers from highest (1) to lowest (22) projected cases or deaths in 2021               |
| Survival | Predicted 5-year net survival for cases diagnosed in 2015—2017   |
| Trend    | Direction of most recent trend in incidence or mortality rate using data from 1984 to 2019; reflects statistically |
|          | significant increase $(\uparrow)$ or decrease $(\downarrow)$ or no change $( ightarrow)$                           |

Cancer-specific stats 2021